FSH Is Suddenly in the News. We’ve Been Measuring It for 25 Years.
Follicle-stimulating hormone, or FSH, has been showing up with surprising frequency in menopause and longevity discussions lately. Some of the coverage makes it sound as though medicine has just discovered another hormone that changes as women approach menopause.
We have been measuring FSH in women for more than 25 years.
For clinicians who have spent years following women through their 40s, 50s and beyond, the rise in FSH is familiar physiology. It has long helped us understand declining ovarian function, changing follicular activity and the progression from the reproductive years through perimenopause and menopause.
What has become more interesting is the research asking whether FSH may tell us something beyond ovarian function. Investigators are studying its relationship to bone, body composition, metabolism and the brain. Some researchers are going further and asking whether FSH itself participates in these changes rather than simply reflecting what is happening in the ovaries.
That is an intriguing scientific question. It is also a very different claim from saying that FSH has suddenly become a new longevity biomarker or something physicians should try to suppress.
One-Minute Read
FSH is produced by the pituitary gland and plays a central role in ovarian function. As the ovarian follicle pool declines with age, inhibin B generally falls and the pituitary responds by increasing FSH. This process often begins well before the final menstrual period.
Long-running research from the Study of Women’s Health Across the Nation found that FSH began its sustained rise roughly six years before the final menstrual period, while the sustained decline in estradiol occurred considerably later. This is one reason a woman can have a rising FSH while estrogen remains variable, and at times quite robust, during perimenopause.
More recent research is examining whether increasing FSH is associated with changes outside the reproductive system. The evidence is especially interesting for bone. Emerging animal and human research is also exploring FSH signaling in the brain and possible relationships with cognitive aging and Alzheimer’s disease biology.
For now, FSH remains most useful when interpreted as part of the larger clinical picture. There is no established “optimal FSH” for longevity, and lowering FSH itself is not an accepted treatment goal.
What FSH Has Always Told Us
FSH is made by the anterior pituitary gland. During the reproductive years, it helps recruit and develop ovarian follicles and supports the production of estradiol.
The ovaries, in turn, send signals back to the brain and pituitary. One of those signals is inhibin B, produced primarily by granulosa cells of developing ovarian follicles. As the number and responsiveness of follicles decline with reproductive aging, inhibin B falls. The pituitary receives less negative feedback and produces more FSH in an effort to stimulate the remaining follicles.
This is why rising FSH has been part of the clinical language of ovarian aging for decades.
It is also why FSH should not be viewed in isolation. During perimenopause, ovarian activity can become remarkably variable. FSH can rise, fall and rise again. Estradiol may be low during one part of the transition and surprisingly high during another. Ovulation becomes less predictable and progesterone exposure often changes as cycles become irregular.
A single hormone value cannot describe an entire menopausal transition. Age, menstrual pattern, symptoms, medications, medical history and the broader hormonal picture all contribute to interpretation.
FSH Often Changes Before Estrogen Clearly Falls
This part of the story is important because it corrects an overly simple description of menopause as a process in which estrogen just gradually declines.
It often does not happen that neatly.
Longitudinal data from the Study of Women’s Health Across the Nation, commonly known as SWAN, followed hormone changes in women as they approached their final menstrual period. In that analysis, the FSH trajectory began increasing approximately 6.1 years before the final menstrual period and accelerated approximately two years beforehand. The sustained decline in estradiol began much later, at roughly two years before the final menstrual period.
Earlier endocrine research also demonstrated that declining inhibin B and the reduction in the ovarian follicle pool help drive the early increase in FSH.
For a physician following a woman over time, this is much more useful than the idea that one hormone simply switches off and another switches on. Reproductive aging is a dynamic endocrine transition.
Why Some Guidelines Say You Do Not Need an FSH Test
There is an apparent contradiction in current menopause medicine. FSH is receiving more scientific attention at the same time that several clinical guidelines discourage routine FSH testing simply to diagnose menopause in otherwise healthy women over 45.
Both positions can be reasonable.
If a 52-year-old woman has characteristic menopausal symptoms and has gone 12 months without menstruating, an FSH level usually is not necessary to establish that she is menopausal. Organizations including the American College of Obstetricians and Gynecologists and the United Kingdom’s NICE guideline emphasize clinical history rather than routine hormone testing for that purpose.
That does not make FSH biologically irrelevant.
Using FSH as a required diagnostic test for menopause and using FSH to understand reproductive endocrinology are two different clinical questions.
There are also situations in which laboratory testing can provide useful context, particularly when the clinical picture is unclear, menopause appears unusually early, ovarian function needs to be evaluated, or a physician is trying to understand the broader endocrine pattern rather than simply attach a menopause label.
The Bone Connection Is Particularly Interesting
Menopause-related bone loss has traditionally been explained primarily through declining estrogen. Estrogen remains critically important to skeletal biology, but research over the past two decades has raised another possibility: rising FSH may be associated with bone loss independently of some of the effects of estradiol.
SWAN investigators reported in 2019 that higher FSH during the menopausal transition helped identify women more likely to experience significant bone mineral density loss. At the lumbar spine, each doubling of FSH was associated with a substantially greater likelihood of significant bone loss in the following year. FSH was more informative than estradiol for identifying impending bone loss at the lumbar spine in that analysis.
More recent work continues to examine this relationship, including studies evaluating FSH alongside bone density across the menopausal transition.
This does not mean that clinicians should begin treating an FSH number to protect bone. It does suggest that the familiar hormonal transition around menopause may be biologically richer than the older explanation of estrogen deficiency alone.
For us, the practical response remains comprehensive bone assessment when appropriate: bone density, body composition, resistance exercise, adequate protein, calcium and vitamin D status, medication and hormone history, fall risk and the other factors that determine whether a woman maintains skeletal strength as she ages.
FSH and the Brain: Promising Research, but Early Research
The area generating some of the greatest recent interest is the brain.
In 2022, researchers writing in Nature reported that FSH acted on neurons in mouse models of Alzheimer’s disease. Increasing FSH signaling accelerated amyloid-beta and tau pathology and impaired cognition in those models. Blocking FSH signaling improved the Alzheimer-like phenotype.
Animal research can help uncover mechanisms, but a mouse model is not a postmenopausal woman. The important question has been whether meaningful human evidence would follow.
A study published in 2026 examined 884 postmenopausal women age 60 and older across a spectrum ranging from normal cognition to mild cognitive impairment and Alzheimer’s dementia. Higher serum FSH was associated with poorer cognitive performance and greater cerebral amyloid-beta deposition measured with PET imaging. Estradiol did not show the same association in that analysis.
Those findings deserve attention, but they should not be turned into clinical certainty. The study demonstrated an association. It did not establish that high FSH causes Alzheimer’s disease, that an individual woman’s FSH predicts whether she will develop dementia, or that reducing FSH will prevent cognitive decline.
FSH is not currently an Alzheimer’s screening test.
What the research does accomplish is to give scientists another plausible pathway to investigate as they try to understand why the menopausal transition intersects with changes in brain metabolism, vascular health, sleep, body composition and long-term cognitive risk.
What About Weight and Metabolism?
This area is less settled.
Laboratory and animal studies have suggested that FSH signaling may affect adipose tissue, thermogenesis and energy metabolism. Human studies have produced a more complicated picture. Some longitudinal findings have associated increasing FSH with gains in body fat, while other research in older postmenopausal women has found higher FSH associated with lower adiposity.
That inconsistency is useful. It reminds us not to turn an interesting biological mechanism into a clinical conclusion before the human evidence is mature.
The changes in body composition that often accompany midlife are influenced by multiple factors: ovarian hormones, aging, insulin sensitivity, sleep, physical activity, muscle mass, nutrition, medications and genetics among them. FSH may eventually prove to be one piece of that physiology, but it is unlikely to be the entire explanation.
Should We Be Trying to Lower FSH?
At this point, no.
Hormone therapy can alter FSH through normal endocrine feedback, but reducing the laboratory value itself is not an established therapeutic objective. There is no validated longevity target for FSH and no evidence-based FSH level that physicians should attempt to achieve to protect the brain, skeleton or metabolism.
That distinction is important clinically because medicine has a long history of converting associations into targets before we know whether changing the target actually changes the outcome.
FSH deserves study. It deserves thoughtful interpretation. It does not yet deserve a treatment protocol built around suppressing a number.
Why We Still Measure Hormones
The current discussion around FSH illustrates why we have never viewed laboratory testing as a contest between “test everything” and “testing is unnecessary.” The useful question is whether a test helps us understand the patient in front of us.
A laboratory value has to live inside a clinical history.
For a woman moving through perimenopause, that history may include changes in menstrual cycles, sleep, vasomotor symptoms, mood, cognition, sexual function, body composition, insulin sensitivity, cardiovascular risk and bone health. FSH can contribute information about the reproductive endocrine transition, particularly when interpreted alongside the rest of that picture.
The newer research may eventually give us additional reasons to pay attention to it.
For now, the most interesting development is not that medicine has rediscovered an old laboratory test. Researchers are asking better questions about what the hormonal changes of menopause may be doing throughout the body.
After more than two decades of measuring FSH, we welcome that conversation.
Medicine, Not Marketing.
Selected References
Randolph JF Jr, et al. Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period. J Clin Endocrinol Metab. 2011. PubMed
Greendale GA, et al. Estradiol and follicle-stimulating hormone as predictors of onset of menopause transition-related bone loss in pre- and perimenopausal women. J Bone Miner Res. 2019. PubMed
Xiong J, et al. FSH blockade improves cognition in mice with Alzheimer’s disease. Nature. 2022. Nature
Wang SM, et al. Follicle-stimulating hormone linked to cognitive decline and amyloid burden in postmenopausal women. Front Aging Neurosci. 2026. PubMed
Sims S, et al. FSH signaling in osteoporosis and Alzheimer’s disease. Curr Osteoporos Rep. 2026. PubMed
Puranda JL, et al. Calcium, FSH, and the changing bones of menopause: a longitudinal look at the silent transformation. Bone. 2026. PubMed
American College of Obstetricians and Gynecologists. Do I need to have testing of my hormone levels during perimenopause? 2025. ACOG
National Institute for Health and Care Excellence. Menopause: identification and management. NG23. NICE
This article is part of the HormoneSynergy® Longevity Medicine education series covering preventive cardiology, metabolic health, hormone optimization, body composition, and advanced diagnostics for healthy aging.
Return to the Longevity Medicine Guide →